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Abstract
Objectives—To explore whether HPV-related biomarkers predict oropharyngeal squamous cell 
cancer (OPSCC) survival similarly across different global regions, and to explore their prognostic 
utility among non-oropharyngeal (non-OP) head and neck cancers.
Methods—Data from 1362 head and neck SCC (HNSCC) diagnosed 2002-2011 was used from 
epidemiologic studies in: Brazil (GENCAPO study, n=388), U.S. (CHANCE study, n=472), and 
Europe (ARCAGE study, n=502). Tumors were centrally tested for p16INK4a and HPV16 DNA 
(by PCR). Risk of mortality was examined using Cox proportional hazard models.
Results—There were 517 OPSCC and 845 non-OP HNSCC. Cases were primarily male (81%), 
ever smokers (91%), with median age of 58 years and median follow-up of 3.1 years (IQR=1.4- 
5.9). Among OPSCC, the risk of mortality was significantly lower among 184 HPV-related (i.e., 
p16+/HPV16+) compared to 333 HPV-unrelated (p16− and/or HPV16−) cases (HR=0.25, 
95%CI=0.18- 0.34). Mortality was reduced among HPV-related OPSCC cases from the U.S., 
Europe, and Brazil (each p≤0.01) and after adjustment, remained significantly reduced (aHR=0.34, 
95%CI=0.24- 0.49). Among non-OP HNSCC, neither p16 (aHR=0.83, 95%CI=0.60-1.14), HPV16 
DNA (aHR=1.20, 95%CI=0.89-1.63), or p16+/HPV16+ (aHR=0.59, 95%CI=0.32-1.08) was a 
significantly predictor of mortality. When interaction was tested, the effect of HPV16/p16 was 
significantly different in OPSCC than non-OP HNSCC (p-interaction=0.02).
Conclusion—HPV-related OPSCCs had similar survival benefits across these three regions. 
Prognostic utility of HPV among non-OP HNSCC is limited so tumor HPV/p16 testing should not 
be routinely done among non-OP HNSCC.
Keywords
oral HPV; p16; non-OP; prognostic; risk factors; Brazil; Europe; HPV; survival; HNSCC
Introduction
Head and neck squamous cell carcinoma cancer (HNSCC) has an estimated global annual 
burden of more than 500 000 incident cases and 300 000 deaths.[1] The incidence of 
HNSCC caused by human papillomavirus (HPV) is increasing in many high-income 
countries, but not in other areas.[2] Questions remain regarding the role of geographic 
differences in HPV associated HNSCC.[3]
Several recent studies suggest HPV-related biomarkers have utility in predicting HNSCC 
survival.[4–10] Due to the improved survival in these cases, different staging for HPV-
related oropharyngeal cancers has even been proposed,[11,12] and several HPV-OPSCC de-
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escalation trials are being conducted.[13,14] However, recurrence remains an issue for HPV-
related OPSCC patients, and it is unclear which patients may benefit from de-escalated 
therapy or de-intensified follow-up. Many questions remain, including whether HPV-related 
biomarkers also have utility in identifying better survival among non-oropharyngeal 
HNSCC. In addition, given the global geographic variation in the role of HPV, it is not 
known whether these biomarkers have consistent prognostic utility across different regions. 
We therefore performed a large international study to rigorously evaluate the ability of 
biological and behavioral markers to predict HNSCC survival.
Materials and Methods
Study Population and design
This analysis is based on cases derived from case-control studies of HNSCCs in three 
distinct regions[15]. Studies included: the Brazilian Head and Neck Genome Project 
(GENCAPO; Southern Brazil – São Paulo)[16], the Carolina Head and Neck Cancer Study 
(CHANCE, North Carolina, U.S.A.)[17] and the Alcohol Related Cancers and Genetic 
Susceptibility in Europe study (ARCAGE).[18] Data from ARCAGE included cases from 
Germany (36%, n=181), Italy (52%, n=259), and U.K (12%, n=62). All cases were enrolled 
into their respective studies between 2002 and 2011 (US cases enrolled 2002-2006) and 
prognostic data was collected prospectively by each cohort. The design was for each study to 
contribute 400-500 HNSCC cases, including at least 110 OPSCC. For each case, studies 
provided paraffin embedded tumor tissue, risk factor survey data, and cancer characteristics, 
as well as prognosis and recurrence (obtained through medical record abstraction and cancer 
registry matching). Data from each study was harmonized by the study datacenter (G.D., 
D.B., and D.A), which compared all study surveys and centralized data into comparable 
categories. Detail on data collection and harmonization were previously reported.[15].
Tumor HPV and p16 testing
Tumors were tested centrally at IARC. p16INK4a expression (called p16 hereafter) was tested 
using immunhistochemistry, according to the protocol provided with the CINtec Histology 
p16 Kit (9511, mtmlabs). Expression was scored using a composite score based on the 
percentage of stained cells (0%=negative[0]; 1-10%[1], 11-50%[2], and 51-80%[3], 
81-100%[4]=diffusely positive) and the intensity of the nuclear or cytoplasmic staining 
(no[0], weak[1], moderate[2], or strong[3] staining). The final score was determined by 
multiplying the extent of positivity scores of stained cells (0-4) with the intensity scores 
(0-3); scores of 4 or greater (moderate positivity in more than 10% of cells) were considered 
positive for p16 expression.
DNA was extracted from paraffin embedded tumor tissues manually and HPV genotyping 
was performed using the type specific E7 polymerase chain reaction bead-based multiplex 
method (E7-MPG, IARC, Lyon, France).[19,20] This assay detects all 18 high-risk HPV 
types, but as HPV16 causes the vast majority of HPV-related OPSCC[15], only HPV16 is 
considered in this paper (prevalence of other HPV types detected has been reported 
elsewhere).[15] Five percent of tumors were randomly included as genotyping duplicates. 
Agreement between duplicates was 97%. All samples were processed together and blinded.
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Survey Data
Data collected by the CHANCE, ARCAGE, GENCAPO studies is referred to as data from 
the “U.S.”, “Europe”, and “Brazil” hereafter. Tobacco use was measured as, “ever smoke 
cigarettes, cigars, and/or pipes regularly”, with ever regular chewing tobacco use also 
included in the definition of every tobacco use for the U.S. study only. Regular use was 
defined in these studies as: ever 100 cigarettes or equivalent of other tobacco product (U.S.), 
at least once a week for a year (Europe), and daily for a year (Brazil). Cumulative tobacco 
use was calculated as pack-years of cigarette use plus cigar-years (where 1 cigar equaled 5 
cigarettes), plus pipe-years (where 1 pipe equaled 4 cigarettes) plus in the Brazilian study 
hand-rolled cigarettes (where 1 hand-rolled cigarette equaled 5 store-bought cigarettes).
Regular alcohol use was measured as “ever drink alcoholic beverages regularly”, where 
regularly was defined as: ever (U.S. and Europe), and at least once a month (Brazil). 
Cumulative alcohol use was calculated as the sum of drink-years for beer, wine, and liquor 
drinking. One drink of alcohol was defined as 330mL (12oz) for beer, 125mL (4oz) for 
wine, and 50mL or one shot for liquor. A drink-year was considered two drinks per day for 
one year. The drink-years for beer, wine, and liquor were summed for the cumulative alcohol 
“drink-year” measure.
Cancer characteristics and survival
Tumor sub-site was classified as oropharynx (ICDO C01.9, 02.4, 09.0-10.9), hypopharynx 
(ICDO C13.0-13.2, 13.8), larynx (C32.0-23.2, 32.8-32.9), or oral cavity (C00.0-00.9, 
02.0-02.3, 02.8-03.1, 03.9-04.1, 04.8-05.0, 05.8-06.2, 06.8-06.9). All other sites were 
excluded. All non-OP HNSCCs that were HPV16-positive had sub-site reconfirmed by local 
site re-review of all records. Tumor stage was classified using TNM grouping based on the 
AJCC cancer staging handbook and atlas sixth edition[21], and was available in 89% of 
cases including 96% of U.S., 75% of Europe and 98% of Brazil cases. Missing stage data in 
the European study was because the ARCAGE study was initially designed with a focus on 
risk factors for cancer occurrence, and comprehensive collection of clinical data was not 
emphasized during the initial years of the study.
Overall survival and disease-specific survival were collected by each study. Recurrence was 
collected by the European and Brazilian study but not the U.S. study. Follow-up was 
obtained from each cohort as the date of last confirmed contact, vital status at censor, and 
date of death (if applicable). Linkage with national death files was performed by all three 
studies (in the Brazilian study this matching was only done for participants with missing or 
unconfirmed information). In addition, linkage with cancer registry data was performed by 
all three studies (except the German site of the ARCAGE study, which relied on medical 
record abstraction for cancer confirmation and details).
Statistical Analysis
Characteristics of cases were compared between region/studies using chi-squared for 
categorical and test of medians for continuous variables. The primary analysis defined cases 
as HPV-related if they were both p16-positive and HPV16 DNA-positive, and defined cases 
as HPV-unrelated if they were p16-negative and/or HPV16 DNA-negative. We also 
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examined associations with survival when considering tumor p16 status alone (negative/
positive) or tumor HPV16 DNA status alone (negative/positive).
Predictors of overall survival (all-cause mortality) were evaluated using Cox proportional 
hazard models. Predictors were explored for all HNSCC, and when stratified by sub-site 
(OPSCC, non-OP HNSCC), and by region/cohort. Mortality was also explored using Kaplan 
Meier curves stratified by sub-site (oral cavity, oropharynx, hypopharynx, larynx), region/
cohort (Brazil, Europe, U.S.), and tumor p16/HPV16 status. The joint effects of HPV and 
tobacco use on survival were also considered by combining tumor HPV/p16 and tobacco 
pack-years (pkyr); as survival was similar among smokers with <20 and those with ≥20 pkyr 
these groups were further combined into ever smokers (≥1 pkyr), within each HPV strata.
Results
Characteristics of cases
There were 1362 incident HNSCCs included in this analysis, all diagnosed between 
2002-2011. This included cases from the U.S. (n=472), Europe (n=502), and Brazil (n=388). 
There were 517 oropharyngeal, 397 laryngeal, 382 oral cavity, and 66 hypopharyngeal SCC. 
Cases were primarily male (81%), ever smokers (91%), ever drinkers (90%) and had a 
median age at diagnosis of 58 years (Table 1).
There were many similarities in the characteristics of cases in each of the three regions. In 
each region, most cases were male, ever smokers with a high median pack-year, and were 
primarily 50-69 years of age at diagnosis (Table 1). However, there were some notable 
differences in case characteristics between regions. For example, a larger proportion of 
OPSCC cases in the study were from the U.S. (47%) than from Europe (22%) or Brazil 
(31%, p<0.001). Cases from Brazil were significantly more likely to be male, stage IV, to 
have 40 or more pack-years, 40 or more drink-years, and to have died from HNSCC, 
compared to cases from Europe and the U.S. (Table 1).
As previously reported, p16/HPV16 positivity was higher among OPSCC than non-OP 
HNSCC cases (35% vs 4%, p<0.001).[15] The proportion of OPSCC that were HPV-related 
varied significantly by region from 4.1% in Brazilian and 31% in European to 59% of U.S. 
OPSCCs (p<0.001).[15]
Case Follow-up
Median follow-up after HNSCC diagnosis was 3.1 years (IQR= 1.4- 5.9). There were 653 
deaths observed during 5600 total person-years of follow-up. There were 179 recurrences 
among 3242 person-years of follow-up in Brazil & Europe (U.S. cohort did not have 
recurrence data). Median survival was significantly lower among hypopharyngeal cases (3.5 
years), than oropharyngeal (5.7 years), oral cavity (5.6 years), and laryngeal (7.3 years) 
cases (p=0.005); Supplementary Fig. S1. These survival differences, in part reflected 
differences in stage at diagnoses between case sites, as only 11% of hypopharyngeal cases 
were early stage (stage 1-2), compared with 14% of oropharyngeal, 42% of oral cavity, and 
38% of laryngeal cases (p<0.001).
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There were 517 OPSCC followed for 2310 person-years, including 269 deaths. Median 
OPSCC survival was 5.7 years and causes of death included death from HNSCC (n=162, 
60%), from other cancer (n=68, 25%), from a non-cancer cause (n=32, 12%), and 7 (3%) 
deaths for whom cause was not known. Among 845 non-OP HNSCC followed for 3290 
person-years, there were 384 deaths. Median survival for non-OP HNSCC was 6.2 years, 
and causes of death included deaths from HNSCC (n=207, 54%) from other cancer (n=78, 
20%) from a non-cancer cause (n=73, 20%), and 26 (7%) deaths for whom cause was not 
known.
Predictors of OPSCC Survival
As described in Table 2, among OPSCCs there was a significantly lower risk of death among 
184 HPV-related (i.e. p16+/HPV16+) compared to 333 HPV-unrelated (i.e. p16− and/or 
HPV16−) cases (HR=0.25, 95%CI=0.18-0.34). Similar differences were observed when 
considering tumor p16-positivity alone (HR=0.32, 95%CI=0.25-0.42; Supplementary Fig. 
S2) or tumor HPV16 DNA positivity alone (HR=0.36 95%CI=0.27-0.46). Three year overall 
survival was 82% among HPV-related OPSCCs compared to only 45% among HPV-
unrelated OPSCC (p<0.001). This reduction in risk of death among HPV-related OPSCC 
cases was consistently observed in the U.S. (p<0.001), Europe (p=0.01), and Brazil 
(p=0.02), (Figure 1; Table 2).
In unadjusted analysis among OPSCC, the risk of death was higher in Europe (HR=1.89, 
95%CI=1.36-2.64) and in Brazil (HR=2.97, 95%CI=2.23-3.96) than in the U.S. (Table 3). 
After adjusting for HPV, age, stage, sex, tobacco and alcohol use, risk of death was similar 
in Europe and the U.S. but remained elevated among cases from Brazil (aHR=1.68, 
95%CI=1.21-2.35). Other significant risk factors for increased OPSCC mortality included 
higher cancer stage (stage 4 vs 1 aHR=2.05, 95%CI=1.03- 4.06), ever regular tobacco use 
(aHR=3.20, 95%CI=1.47- 6.96), and older age (per 10-year increase, aHR=1.15, 95%CI 
1.00-1.33), Table 3. Risk of death remained significantly lower among HPV-related 
compared to HPV-unrelated OPSCC (aHR=0.34, 95%CI=0.24- 0.49). As shown in Figure 2, 
three year survival was lowest among HPV-unrelated ever smokers (44%), moderate among 
both HPV-unrelated never smokers (74%) and HPV-related ever smokers (78%) and highest 
in HPV-related never smokers (93%), p<0.001. When examining all cases of HNSCC, risk 
factors for mortality were similar to those for OPSCC (Table 3).
We subsequently explored survival among HPV-related OPSCC cases, using recently 
proposed prognostic risk groupings that included both stage, age, and smoking pack-years.
[22] Among HPV-related OPSCCs in this study, overall survival at 3 years was high among 
stage 1-3 cases whether they had ≤ 20 pkyr (group I) or >20 pkyr (group II), 90% and 91%, 
respectively. Survival among stage 4 HPV-related OPSCCs was 80% and 55% among those 
≤ 70 years old (group III) and >70 years old (group IV), respectively. Survival was lower 
among HPV-unrelated OPSCC than HPV-related OPSCC within each of these groups (each 
p<0.001).
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Predictors of non-OP HNSCC Survival
The predictive utility of HPV16 and p16 among non-OP HNSCC was less clear than that 
among OPSCC (Figure 3). In univariate analysis among non-OP HNSCC, HPV-related cases 
had significantly lower risk of death compared to HPV-unrelated cases (HR=0.55, 
95%CI=0.31-0.97). This difference was observed among non-OP HNSCC cases from both 
the U.S. (HR=0.61, 95%CI=0.28-1.32) and Europe (HR=0.56, 95%CI=0.23-1.35); no 
HPV16+/p16+ non-OP HNSCC cases were detected in Brazil. When considering only p16 
tumor status (HR=0.74, 95%CI=0.57-0.96, Table 2) the effect on survival was attenuated 
and when considering only tumor HPV16 DNA (HR=0.93, 95%CI=0.72-1.20) there was no 
association (Table 2).
After adjusting for other risk factors, neither p16 alone (aHR=0.83, 95%CI=0.60-1.14), or 
HPV16 DNA alone (aHR=1.20, 95%CI=0.89-1.63) was a significantly predictor of risk of 
death among non-OP HNSCC. Risk of death was reduced, although no longer statistically 
significant, when using the more specific combined HPV16+/p16+ marker for an HPV-
related compared to an HPV-unrelated non-OP HNSCC cases (aHR=0.59, 
95%CI=0.32-1.08). Results were similar when disease-free survival was considered (results 
not shown). Risk factors for survival among non-OP HNSCC included a significant 
independent effect of older age (per 10-year increase, aHR=1.22, 95%CI=1.09-1.37), higher 
stage (stage 4 vs 1, aHR=1.93, 95%CI=1.40-2.66) and ever regular alcohol use (aHR=1.68, 
95%CI=1.08-2.59). Patients with laryngeal tumor site had significantly lower risk of death 
compared to those with oral cavity cancers (aHR=0.72, 95% CI=0.57-0.91). Risk of death 
among non-OP HNSCCs was higher among Brazilian than U.S. (or European) cases in 
unadjusted analysis (HR=1.33, 95%CI=1.09-1.89), but after controlling for other risk 
factors, survival was similar across regions (Table 3).
When interaction between tumor site and HPV16+/p16+ was formally tested, a significantly 
different effect of HPV16+/p16+ on survival was observed among OPSCC than non-OP 
HNSCC (p-interaction=0.01). After adjusting for other factors, this difference remained, 
with a significant reduction in mortality observed among HPV16+/p16+ OPSCCs 
(aHR=0.29, 95%CI=0.08-1.06) but not among HPV16+/p16+non-OP HNSCC (aHR=0.68, 
95%CI=0.37-1.24) cases (p-interaction=0.02).
Recurrence
Recurrence was explored among the European and Brazilian cases, as the U.S. cases did not 
have recurrence information. There were 179 recurrences observed, including 74 recurrences 
among 271 OPSCC and 105 recurrence among 576 non-OP HNSCC. Risk was lower in 
HPV-related than HPV-unrelated OPSCC for both recurrence (2-year recurrence 12% vs. 
32%, 5-year recurrence 15% vs 36%, p=0.01) and disease-free survival (DFS; 3-years: 88% 
vs 66%, p=0.01; aHR=0.53 95%CI=0.19-1.43). Among non-OP HNSCC this difference in 
recurrence for HPV-related and HPV-unrelated was less clear (2-year recurrence 0% vs. 
14%, 5-year recurrence 6% vs 21%, p=0.21).
D'Souza et al. Page 7
Oral Oncol. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Discussion
This is one of the first large studies to examine the prognostic utility of HPV biomarkers 
among HNSCC across continents, using centralized testing and controlling for other risk 
factors. While the proportion of OPSCC caused by HPV varied widely by region, HPV-
related OPSCC cases had similar survival benefits across these different continents. Tumor 
p16 and HPV16 DNA positivity both were strong biomarkers for improved survival among 
OPSCC, but their prognostic utility was not as clear among non-OP HNSCC.
The utility of tumor HPV16 and p16 as diagnostic markers among OPSCCs is now well 
established.[9,23,24] The reduction of risk of death among HPV-related OPSCCs in this 
study was stronger than some previous studies,[5,25] but was similar in magnitude to some 
other studies.[6,26,27] Given better survival among HPV-related OPSCC, treatment de-
intensification has been suggested and is currently being investigated.[23] This study 
suggests that HPV-related markers had similar prognostic utility among OPSCC across 
different countries and continents.
This study suggests that tumor p16 and HPV16 positivity do not have as much prognostic 
utility among HNSCC outside of the oropharynx, especially after accounting for other risk 
factors. This is consistent with several previous studies suggesting p16 and/or HPV are not 
predictors of survival among laryngeal[11,12] or hypopharyngeal[12] SCC. In contrast, an 
RTOG study did report significant prognostic utility of p16 among non-OP HNSCC (which 
included a group of 80 oral cavity, 181 laryngeal, and 61 hypopharyngeal cases).[28] 
However, similar to our study, this RTOG study also reported significant interaction of p16 
with tumor site (i.e. that the effect of HPV was significantly stronger among OPSCC than 
non-OP HNSCC), and found no prognostic effect of HPV ISH among non-OP HNSCC.
Taken together, this research suggests that p16 and HPVPCR likely do not have prognostic 
use when used alone among non-OP HNSCC. In our study, when a more specific definition 
requiring both p16-positivity and HPV16-positivity was used, cases with this dual positivity 
appeared possible have improved survival, but survival was not statistically significantly 
different (similar to findings in the RTOG trial for dual positivity).[28] This is consistent 
with a recent study of 142 hypopharyngeal cases which reported prognostic utility when 
using dual HPV16DNA/P16 positivity.[29] The lack of an association between tumor 
HPV16 DNA detection and risk of death among non-OP HNSCC underscores that the 
prognostic utility of this testing is limited to OPSCC. Other risk factors among non-OP 
HNSCC were consistent with previous research, highlighting the importance of stage, age, 
tobacco and alcohol use. Alcohol use and intensity were significant independent predictor of 
non-OP HNSCC survival across all three regions.
Median survival was notably longer among US than European or Brazilian cases. This is in 
part explained by the higher proportion of HPV-related OPSCC cases in the U.S. and lower 
prevalence of co-factors such as tobacco use in the U.S. In multivariate models, region was 
not a significant predictor of mortality among non-OP HNSCC, but mortality did remain 
higher among Brazilian OPSCC. This suggests there may be other diagnostic or treatment 
related factors among OPSCC contributing to OPSCC survival differences.
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This study had several limitations and strengths. First, information on tobacco and alcohol 
use was collected with different survey instruments in each of the three studies. However, 
each study collected in-depth information on these risk factors directly from the participants 
(not through medical record abstraction) with clear definitions which could then be 
harmonized by the datacenter. There was variation in the number of cases with each tumor 
site from each study. While we cannot exclude the possibility that misclassification of some 
case sites could have occurred and might have influenced the proportion of HPV-related 
OPSCC cases if it occurred all tumor sites, designations were carefully reviewed by each 
study, with a second review of tumor site for all HPV-related non-OP HNSCC cases. All 
tumor samples were tested centrally and blinded to subsite in the same laboratory. We could 
not differentiate between stage IV A, B, and C or evaluate treatment in this study and thus 
can not exclude that some of the variation in survival observed between regions is explained 
by differences in the proportion of stage IVC cancers and/or in therapy.
This is one of the first large epidemiologic studies with centralized testing to compare the 
effect of HPV on OPSCC and non-OP HNSCC survival across continents. We found similar 
reductions in mortality for HPV-related OPSCC across each region. p16 and HPV16 DNA 
each showed utility in predicting mortality when used alone or in combination, particularly 
for OPSCC. The limited prognostic utility of p16 and HPV16 DNA status when used alone 
for non-OP HNSCC may suggest they should not be used for non-OP HNSCC. Although the 
impact of HPV on HNSCC varies by region, with large differences in the proportion of 
OPSCC cases caused by HPV, this study suggests there are HPV-related OPSCC cases in 
each region with similarly high survival.
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Highlights
• HNSCC survival was poorer among cases in Brazil than in the US and 
Europe
• HPV+/p16+ OPSCC predicted lower mortality in all 3 regions (US, 
Europe, Brazil)
• HPV was not prognostic among non-OP HNSCC (OC, larynx, and HP)
• Effect of HPV/p16 was significantly different in OPSCC & non-OP 
HNSCC
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Figure 1. 
Overall survival among oropharyngeal squamous cell patients with HPV16 DNA 
positive/p16 positive (HPV-related) compared to HPV16 or P16 negative (HPV-unrelated) 
tumors, for the US (panel A), Europe (panel B), and Brazil (panel C).
Median survival was significantly higher among HPV-related than HPV-unrelated OPSCC in 
the U.S (n=242; 3.4 years vs. median not reached, p<0.001), Europe (n=112; 2.2 years vs. 
median not reached, p=0.01), and Brazil (n=163; 1.5 years vs. median not reached, p=0.02).
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Figure 2. 
Survival of 514 oropharyngeal squamous cell cancers by tumor HPV status and history of 
tobacco use.
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Figure 3. 
Overall survival among patients with HPV16 DNA positive/p16 positive (HPV-related) 
tumors compared to those that are HPV16 or p16 negative (HPV-unrelated), for all 1362 
head and neck squamous cell cancers(panel A), 517 oropharyngeal squamous cell cancers 
only (panel B), and 845 non-oropharyngeal head and neck squamous cell cancers only 
(panel C).
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Table 1
Characteristics of study population, overall and by study site.
Characteristic U.S. Europe Brazil Total P-value
N= 472 N= 502 N= 388 N= 1362
N (%)
Sex Men 363 (77) 398 (79) 344 (89) 1105 (81) <0.001
Women 109 (23) 104 (21) 44 (11) 257 (19)
Smoking Pack-yearsa Never 58 (12) 50 (10) 11 (3) 119 (9) <0.001
<10 60 (12) 40 (8) 21 (5) 121 (9)
10-19 30 (6) 41 (8) 33 (9 104 (87)
20-29 34 (7) 58 (12) 32 (8) 124 (9)
30-39 68 (15) 96 (19) 71 (18) 235 (17)
≥ 40 220 (47) 214 (43) 218 (57) 652 (48)
Median among users (IQR) 43 (24- 65) 39 (26- 59) 44 (31- 70) 41 (27- 64)
Alcohol consumptionb Never 46 (10) 39 (9) 42 (11) 127 (10) <0.001
<10 95 (20) 111 (27) 33 (9) 239 (19)
10-19 40 (9) 55 (13) 23 (6) 118 (9)
20-29 31 (7) 39 (9) 20 (5) 90 (7)
30-39 20 (4) 27 (7) 13 (3) 60 (5)
≥ 40 235 (50) 146 (35) 253 (66) 634 (50)
Median among users (IQR) 50 (12- 145) 25 (7- 66) 101 (35- 265) 49 (13- 139) <0.001
TNM Stagec I (T1N0M0) 69 (15) 67 (18) 18 (5) 154 (13)
II (T2N0M0) 79 (17) 66 (17) 47 (12) 192 (16)
III (T3N0M0 or T1-3N0M0) 88 (20) 68 (18) 54 (14) 210 (17)
IV (Any M1, T4 or T1-3N2M0) 216 (48) 177 (47) 263 (69) 656 (54)
Sub-site Oral Cavity 123 (26) 154 (31) 105 (27) 382 (28) <0.001
Oropharynx 242 (51) 112 (22) 163 (42) 517 (38)
Hypopharnx 0 (0) 39 (8) 27 (7) 66 (5)
Larynx 107 (23) 197 (39) 93 (24) 397 (29)
Vital Status Died (any cause) 258 (55) 199 (40) 196 (51) 653 (48) <0.001
Died (from HNSCC) 93 (20) 109 (22) 167 (43) 369 (27) <0.001
In Years: Median (IQR)
Age 56 (50- 64) 60 (54- 68) 56 (50- 64) 58 (51- 66) <0.001
Follow-up 8.3 (2.4- 10.0) 2.9 (1.6- 4.5) 1.8 (0.8- 3.4) 3.1 (1.4- 5.9) <0.001
Time to Recurrenced (among those who recurred) n/a 3.9 (1.2- 7.6) 1.6 (0.63- 4.2) 2.7 (0.8- 6.2) <0.001
Time to death (among those who died) 2.7 (1.4- 5.5) 1.3 (0.6- 2.6) 1.0 (0.5- 1.9) 1.5 (0.8- 3.2) <0.001
a
Data missing for 2 each in the U.S. and Brazil, and 3 in Europe
b
Data missing for 94 cases (5 US, 85 Europe, 4 from Brazil).
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cStaging based on AJCC cancer staging handbook and atlas sixth edition. Stage information missing for 124 cases from Europe, 20 from the US 
and 6 from Brazil
d
Information on recurrence was not available for the U.S. (CHANCE) study.
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